Rifamail 300 Capsule contains Rifampicin 300mg, a first-line anti-tuberculosis agent widely used in the treatment of TB and other bacterial infections. It is an essential component of combination therapy for effective TB management.
Rifampicin works by inhibiting bacterial RNA polymerase, preventing protein synthesis and promoting rapid microbial clearance. Its efficacy in multi-drug TB regimens makes it indispensable in clinical practice.
Capsule formulation ensures accurate dosing, stable bioavailability, and ease of administration, supporting better patient adherence. Due to its critical role in TB treatment, Rifamail 300 Capsule maintains high demand in hospitals, clinics, and national TB programs.
Adding Rifamail 300 Capsule to your anti-tuberculosis and anti-infective portfolio enhances your range with a reliable, high-rotation product. Its prescriber trust, institutional adoption, and export potential make it ideal for PCD pharma companies, distributors, and third-party manufacturing partners.